MLC Medical LLC is pleased to announce a strategic partnership with Concord Biotech Limited, an Indian biotechnology company known globally for fermentation-based immunosuppressants.

The partnership brings Mycophenolate Mofetil Capsules, USP (250mg) to the Georgian market. Mycophenolate mofetil is a cornerstone immunosuppressant indicated in combination with corticosteroids and calcineurin inhibitors for preventing allograft rejection in renal, cardiac, and liver transplants.

This partnership expands options for transplant centers, ensuring that organ recipients benefit from reliable, cost-effective maintenance immunosuppression.

MLC Medical anticipates a strong relationship with Concord Biotech as we continue broadening access to vital post-transplant medications in Georgia.